Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that in an ex vivo model simulating alopecia areata, the DHODH inhibitor farudodstat reduced T-cell proliferation and MHC protein expression in hair follicles, suggesting it may protect against immune privilege collapse without cytotoxic effects.

In a mouse model study, researchers developed a methacrylated hyaluronic acid-based hydrogel microneedle patch co-loaded with finasteride and a carbon monoxide-releasing molecule for androgenetic alopecia, which showed better hair regrowth and safety compared to traditional treatments, offering an innovative approach with minimized systemic side effects.

In this case report, researchers identified a potential adverse skin reaction, called SDRIFE or Baboon syndrome, caused by the drug tofacitinib in a 19-year-old woman being treated for alopecia subtotalis, leading the authors to recommend discontinuation of the drug.

This study identified a recurrent mutation in the endothelin receptor type A associated with mandibulofacial dysostosis with alopecia, and proposed a mechanism involving increased ligand affinity due to structural changes.

This study used Density Functional Theory to calculate finasteride's molecular properties, finding the GGA/PW91 method aligns well with experimental data and identifying key reactive sites for chemical interactions.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

This meta-analysis found a significant positive association between frontal fibrosing alopecia and both sunscreen and moisturizer use, with the moisturizer association significant only in males.

This study found that ACOD1 deficiency in dermal papilla cells promotes mitochondrial dysfunction and contributes to cellular senescence in androgenetic alopecia, suggesting ACOD1 as a potential therapeutic target and 4-octyl itaconate as a promising treatment option for AGA.

This article reviews frontal fibrosing alopecia, exploring its characteristics, demographics, and associated conditions, and calls for controlled trials due to an increase in worldwide cases; it reports no new findings.

In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.

The researchers reported that adenosine increases FGF-7 expression in dermal papilla cells, which may stimulate hair growth via the A2b adenosine receptor and cAMP pathway.

This study evaluated the 308-nm excimer laser as an adjuvant treatment for frontal fibrosing alopecia and found it may stabilize hairline recession and improve erythema and perifollicular hyperkeratosis, with transient erythema as the only reported adverse effect.

This study found that DEFB1 polymorphisms, specifically the rs1800972 CG and GG genotypes, may predict susceptibility to and severity of alopecia areata.

This article reviews the potential for α-difluoromethylornithine to help control hair growth and prevent cancer, but it does not present new clinical results.

The Fas/FasL pathway may play a role in alopecia areata.

This article discusses frontal fibrosing alopecia, noting potential connections to lichen planopilaris, but reports no new clinical findings.

This review examined the common side effects of FGFR inhibitors like erdafitinib, pemigatinib, and futibatinib, and detailed strategies for managing them, highlighting that proactive monitoring and appropriate interventions can effectively mitigate these toxicities.

This case report highlights that frontal fibrosing alopecia can occur in black patients and may resemble androgenetic alopecia, underscoring the importance of considering FFA when diagnosing frontotemporal alopecia in this population.

In this study, the researchers developed a hydrogel mimicking the fetal environment that significantly accelerated wound healing and hair follicle regeneration in vivo, with over 94% wound closure in 14 days, surpassing hydrogels lacking certain additives.

This study examined the application of new clinical guidelines for diagnosing frontal fibrosing alopecia in 18 men, highlighting that current diagnostic criteria may often overlook early beard involvement and sideburn recession.

This study observed that frontal fibrosing alopecia in postmenopausal women involves selective follicular inflammation, and finasteride treatment may slow disease progression, suggesting a potential androgen-related component.

This study suggests that EDA-A2 induces apoptosis in hair follicles by increasing DKK-1 expression, implicating EDA2R signaling as a potential therapeutic target for androgenetic alopecia.

This review discusses the etiology, pathogenesis, clinical presentation, and treatment of frontal fibrosing alopecia, noting the lack of clinical trial data and limited observational treatment results.

This study found that caffeic acid amide derivative, compound 4, effectively inhibited steroid 5α-reductase type 1 in vitro, suggesting potential for development as a treatment for androgenic alopecia.

This article summarizes dermatologic adverse events in patients treated with afatinib in clinical trials and discusses strategies for managing these side effects, without providing new clinical results.

This pilot study found that examining changes in scalp scales after scraping may effectively distinguish seborrheic dermatitis associated with androgenetic alopecia from fibrosing alopecia in a pattern distribution.

This study reported that while various treatments for frontal fibrosing alopecia showed limited effectiveness, dutasteride most effectively stabilized the condition among patients at Duke University.

This study found that engineered high-affinity soluble CD200R agonists, including ARQ-234, showed superior efficacy in reducing immune responses in various preclinical models of inflammatory conditions, suggesting potential as a therapeutic for atopic dermatitis and other related diseases.